Clarus Therapeutics, a biotech with an oral testosterone replacement therapy entering pivotal Phase 3 trials, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The Northbrook, IL-based company, which was founded in 2003 and has yet to generate product revenue, plans to list on the NASDAQ under the symbol CLRS. Piper Jaffray and Wells Fargo Securities are the lead underwriters on the deal, for which pricing terms and timing were not disclosed.